EP1169088A1 - Procede et appareil de lyse a transducteur double a ultrasons - Google Patents

Procede et appareil de lyse a transducteur double a ultrasons

Info

Publication number
EP1169088A1
EP1169088A1 EP00952781A EP00952781A EP1169088A1 EP 1169088 A1 EP1169088 A1 EP 1169088A1 EP 00952781 A EP00952781 A EP 00952781A EP 00952781 A EP00952781 A EP 00952781A EP 1169088 A1 EP1169088 A1 EP 1169088A1
Authority
EP
European Patent Office
Prior art keywords
ultrasound
cavitation
transducer
location
clot
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00952781A
Other languages
German (de)
English (en)
Inventor
Uri Rosenschein
Yoram Eshel
Vladimir Furman
Efim Kerner
Izhak Fabian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiosonics Inc
Original Assignee
Angiosonics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiosonics Inc filed Critical Angiosonics Inc
Publication of EP1169088A1 publication Critical patent/EP1169088A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/225—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
    • A61B17/2256—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves with means for locating or checking the concrement, e.g. X-ray apparatus, imaging means
    • A61B17/2258—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves with means for locating or checking the concrement, e.g. X-ray apparatus, imaging means integrated in a central portion of the shock wave apparatus

Definitions

  • the invention relates generally to medical devices and more particularly to a method and apparatus for delivering ultrasound energy to a treatment location within a human or other mammal.
  • ultrasound devices for ablating, lysing or removing material obstructing blood vessels in humans and to otherwise apply ultrasound to locations within the body for therapeutic purposes.
  • One such device for removing material obstructing blood vessels is in the form of an elongated ultrasound transmitting probe.
  • This device includes a cavitation generating tip at the distal end of an elongated transmission member.
  • a transducer is used to convert an electrical signal into longitudinal mechanical vibration, which is transmitted to the tip by the transmission member and causes cavitation within the blood vessel to ablate or lyse the obstruction.
  • non-invasive ultrasound systems can exhibit insufficiently satisfactory results. For example, high power is generally needed to cause adequate lysis. This high power is potentially dangerous and thus, it is desirable to operate a non-invasive system more efficiently, at lower average power, in order to provide a greater margin of safety.
  • the effects of non-invasive ultrasound devices on various locations within the body can also be difficult to predict and control.
  • an apparatus and method for the application of ultrasound to a location within the body is provided.
  • the apparatus can advantageously operate at a pulse duration below about 100 milliseconds and in the range 0.1 milliseconds to 100 milliseconds and a pulse repetition period below about 1 second and in the range of 1 millisecond to 1 second. 0 Duty cycle ratios over 5 and preferably over 8 are also advantageous.
  • Therapeutic applications of ultrasound such as for assisting in the treatment of medical conditions such as cancer and/or other ailments are also provided.
  • Treatment can be controlled by monitoring the size and location of the cavitation bubble cloud with an ultrasound imaging device and adjusting parameters such as power or pulse length manually 5 and/or automatically to change the size of the cavitation bubble cloud as desired. Treatment can also be controlled by monitoring the sound given off during cavitation.
  • a further object of the invention is to provide a method and apparatus for determining ultrasound application parameters.
  • Yet another object of the invention is to provide an apparatus and method for therapeutic applications of ultrasound.
  • the invention accordingly comprises the several steps and the relation of one or more of such steps with respect to each of the others, and the apparatus embodying features of construction, combinations of elements and arrangements of 0 parts which are adapted to effect such steps, all as exemplified in the following detailed disclosure, and the scope of the invention will be indicated in the claims.
  • FIG. 1A is a schematic perspective view of a system for the non- invasive use and testing of ultrasound energy
  • FIG. IB and IC are front and side views of the transducer shown in FIG 1A;
  • FIG. 2 is a graph showing hydrophone output, in decibels, as a function 0 of transversal displacement of the hydrophone along the Y axis to establish the focal width of ultrasound in the Y direction;
  • FIG. 3 is a graph showing hydrophone output voltage as a function of transducer input voltage, showing that electric potential above 160 volts, and therefore increased wattage, caused a decrease in hydrophone output as a result of exceeding the 5 cavitation threshold of the medium;
  • FIG. 4 is a graph showing hydrophone output voltage as a function of displacement of the transducer along the Z-axis for both short duration pulses and relatively longer duration pulses, showing that a longer pulse duration ( ⁇ ) can initiate cavitation;
  • FIG. 5 is a graph showing hydrophone output voltage as a function of Z- axis displacement for various pulse durations, showing that longer pulse durations were associated with larger decreases in acoustic amplitude after exceeding the
  • FIG. 6 is a graph showing hydrophone output voltage as a function of Z- axis displacement for transducer inputs of varying voltage, showing that cavitation was evidenced by a decrease in actual hydrophone output from the theoretical output;
  • FIG. 7 is a graph showing change in percentage of clot mass dissolution as a function of change in the pulse repetition period (T), showing that an appropriate 0 pulse repetition period has a significant effect on the efficiency of clot lysis;
  • FIG. 8 is a graph showing percentage of clot mass dissolution as a function of pulse duration ( ⁇ ), showing a strong dependency of clot dissolution and danger to the blood vessel on pulse duration;
  • FIG. 9 is a graph showing rate of clot mass dissolution as a function of 5 intensity at the focal area
  • FIGS. 10A and 10B are ultrasound images of a clot within an artery segment, before and after ultrasound treatment
  • FIGS. 11 and 12 are graphs showing microphone output voltage as a function of ultrasound peak intensity in a buffer solution and in a clot, showing that 0 ultrasound initiated randomly, but that once initiated, it could be maintained at decreased intensities and that the threshold and slope are different for the buffer and clot;
  • FIGS. 13 and 14 are graphs showing microphone output as a function of ultrasound intensity, when blood is acted upon by ultrasound of different pulse 5 repetition periods (T), showing that shorter T's correlate to lower intensity thresholds and ultimately lower cavitation intensity;
  • FIGS. 15 and 16 are graphs showing the influence of pulse duration on cavitation activity of a buffer solution and blood, respectively;
  • FIG. 17 is a graph showing microphone output, which is related to cavitation activity, as a function of pulse duration in both a blood and a buffer solution;
  • FIG. 18 is a graph showing percentage of weight loss of a clot as a
  • FIGS. 20A, 20B and 20C are three graphs showing percentage of clot dissolution as a function of pulse duration ( ⁇ ), pulse repetition period (T), and pulse duration ( ⁇ ), respectively, at intensities of 1400 W/cm 2 , 1400 W/cm 2 and 1300 W/cm 2 respectively and shows that optimal parameters can be intensity independent;
  • FIG. 21 is a graph showing percentage of clot dissolution as a function of ultrasound intensity, manifesting threshold for clot lysis;
  • FIG. 22 is a graph showing the weight of unlysed clot as a function of ultrasound intensity, manifesting a threshold for clot lysis
  • FIG. 23 is a perspective view of an invasive type ultrasound 20 transmission system, constructed in accordance with an embodiment of the invention.
  • FIGS. 24-27 are graphs showing cavitation activity as a function of transducer power, showing the difference between continuous and pulsed activation;
  • FIGS. 28-30 show ultrasound probe temperature in activated and unactivated states, both with and without the use of cooling fluid, in a continuous 25 wave mode of probe operation, and in duty cycles of 8;
  • FIG. 31 shows a non-invasive ultrasound treatment system with a combined ultrasound imaging and ultrasound treatment transducer and a display screen permitting an operator to monitor the treatment
  • FIGS. 32A , 32B and 32C show that adjusting pulse duration can affect 30 the size of the cavitation bubble cloud within a vessel. DESCRIPTION OF PREFERRED EMBODIMENTS Significant therapeutic effects can be achieved by applying ultrasound to
  • ⁇ transducer converts an electrical signal to
  • a transducer can be operated in a continuous mode or in a pulsed mode. 0 In a continuous mode, the signal to the transducer is always causing the transducer to generate sufficient vibration to maintain cavitation at the desired location. In a "pulse" mode, the signal amplitude is reduced sufficiently (or eliminated) to permit cavitation to pause between pulses of high amplitude during which cavitation occurs. Certain conventional pulsing methods apply ultrasound in one to several second doses,
  • Non-invasive ultrasound system 100 includes a therapeutic focused ultrasound transducer 110,
  • Therapeutic transducer 110 can be constructed to operate at up to 750 KHz and can be formed with a 1-3 ceramic composite.
  • a 1-3 composite transducer includes rods of PZT inserted into a polymer support and has very high energy transfer efficiency. Front and side views of one embodiment of transducer 110 are shown in FIGS. IB and IC.
  • Therapeutic transducer 110 includes a hole 111 at the center thereof. Hole 111 permits the use of an optional ultrasound imaging probe (not snown) which can guide and monitor the therapy with ultrasound during application.
  • an optional ultrasound imaging probe not snown
  • generator 120 sends a signal 121 through a pair of electric wires 112, which are coupled to transducer 110 at attachment points 113a and ll3b.
  • Signal 121 is formed with a plurality of energy pulses 122 of duration ⁇ at an amplitude (A) and a frequency (f).
  • A amplitude
  • f frequency
  • a pulse will be considered the "on" portion 122 of signal 121, which is of sufficient amplitude to maintain cavitation and is followed by an "off section 123 of signal 121 of insufficient amplitude to maintain cavitation.
  • the duration of time between the beginning of successive pulses 122 is referred to as pulse repetition period T. It has been determined that pulse duration ⁇ is advantageously significantly smaller than pulse repetition period T.
  • Model system 140 includes an open Plexiglas water tank 141 with a hole in a front side 142 for inserting therapeutic transducer 110.
  • Tank 141 was filled with water, which was either degassed or non-degassed, depending on the particular experiment to . be run. When water was not degassed, it included small air bubbles which served as a nuclei for cavitation initiation. Decreasing the number of bubbles in the water increases the energy needed to initiate cavitation.
  • transducer 110 To obtain information about the focal region of ultrasound emitted from transducer 110, a hydrophone (not shown) was positioned at various locations within a dedicated tank. It was found that when activated by generator 120 at low intensities below the cavitation threshold, transducer 110 creates an acoustic field with a focal region having an elongated ellipsoid or cigar shape. To obtain information regarding the effects of ultrasound on clots within a living body, a bovine vessel 150 having a clot 151 therein or a clot attached to the front of a bovine vessel wall was suspended within tank 141 by a specimen holder
  • vessel 150 was filled with either blood 5 or a buffer solution.
  • the vessel 150 and the clot 151 were moved by a computerized x-y positioning a system 180 through a mounting 181 and a computer controller 182.
  • Certain information regarding the effects of applied ultrasound were compiled with an ultrasound imaging device 160, formed with an imaging ultrasound transducer 161, coupled to a processor 162 for interpreting information received from transducer 161
  • Trigger signal 172 corresponds to transducer activation signal 121, so that only sound transmitted from microphone 170 when transducer 110 is activated will be analyzed. .
  • Non-invasive therapeutic ultrasound can be practiced at a frequency of about 100 to 1000 KHz and far broader.
  • Invasive-type (probe-based) therapeutic ultrasound can be practiced at a frequency range of 20 to 100 KHz and far broader.
  • At a frequency of preferably 100 to 1000 KHz advantageous operating parameter include
  • These parameters are particularly well suited for a non-invasive-type device, particularly one applying ultrasound at I > about 750 W/cm 2 , more preferably > about 1000 W/cm 2 .
  • advantageous operating parameters include T ⁇ about 1000 milliseconds preferably ⁇ about 600 milliseconds, more preferably about 100 to 500 milliseconds and/or ⁇ ⁇ about 100
  • - ⁇ j i milliseconds preferably about 10 to 100 milliseconds, more preferably 20 to 60
  • an invasive-type probe can be operated with substantially no cooling fluid.
  • Substantial benefits can be achieved by monitoring the progress of ultrasound treatment. This can be accomplished in at least two ways.
  • a microphone is placed on the body and cavitation can be detected by its audible signal. This can enable an operator to decrease power and/or change the pulse parameters until an acceptable audible signal is detected.
  • a conventional ultrasound imaging transducer is used in conjunction with therapeutic ultrasound. An operator can observe not only a clot being broken up, for example, but the size and location of the cavitation cloud caused by the ultrasound. Thus, an operator can increase or decrease the power as needed, as described above. An operator can also pinpoint the 5 location of the cavitation.
  • changing the pulse duration can change the size of the cavitation cloud. Accordingly, an operator can increase pulse duration in order to increase the size of the cavitation cloud or decrease the pulse duration to decrease the size of the cavitation cloud in order to insure a cloud of appropriate volume. Thus, if desired, the size of the cavitation cloud can be increased to match the size of a clot and decreased if cavitation is occurring in an unneeded location.
  • ⁇ ⁇ other automated systems can detect the pr sence of cavitation, based on the signal received from the imaging transducer. This information can be used to automatically adjust parameters to optimize cavitation. Alternatively, this information can be used to display a cavitation level to a user or to sound a warning or even shut down the system if too much or too little (or none) cavitation is being produced.
  • the two transducers are concentric.
  • the imaging transducer is preferably able to be rotated on the symmetry axis to give a long view, along the length of the vessel, which will appear as two parallel lines and a short axis, through the length of the vessel, which will appear as a ring.
  • the location of the clot can be determined through the ultrasound imaging transducer. To aim the transducer, it is positioned such that the vessel is parallel to one of the X-Y axis of the transducer movement system.
  • a patient 3101 is seen receiving an ultrasound treatment via a transducer unit 3110.
  • Unit 3110 contains an ultrasound imaging transducer concentric with an ultrasound generating transducer.
  • Transducer unit 3110 is coupled via line 3111 to a control unit 3200, which is coupled to a display screen 3210.
  • Display screen 3210 displays the image from the display transducer.
  • an operator can determine the size and location of a cavitation cloud 3301 with respect to a clot 3302 in a vessel 3303.
  • the size and location of cavitation 3301 can be matched to clot 3302 and to vessel 3303.
  • the following examples illustrating the non-invasive application of ultrasound were conducted in a water tank with a system having the general construction shown in FIG. 1A.
  • the hydrophone output was measured in decibels as a function of transversal displacement in mm along the Y axi , parallel to the transducer plane and corresponded to the predicted cigar shape at a distance of 5 cm from the transducer. The results are shown in FIG. 2.
  • Example 2 Example 2
  • Example 4
  • the apparatus shown in FIG. 1A was used to dissolve a blood clot attached to the front of a wall taken from a bovine blood vessel.
  • the operating parameters including a duty cycle of about 8 were deemed acceptable.
  • Example 9
  • a bovine artery segment was filled with non-degassed PBS.
  • Bright reflection images corresponding to cavitation were seen only at the posterior artery wall. This indicated that the transducer was located too close to the vessel. After the transducer was moved away from the vessel, reflection spots, indicating cavitation within the vessel were observed, indicating proper positioning of the transducer.
  • FIG. 10A an ultrasound image of a clot (right side) and buffer solution (dark left side) within a bovine vessel is shown. The focal point of the therapeutic transducer was advanced along the longitudinal axis of the artery segment from left to right. Ultrasound treatment was stopped at approximately the middle of the clot. Referring to FIG. 10B, it can be seen that the dark section indicative of liquid has grown from left to right in the vessel, and the clot has been reduced in size from the ultrasound treatment.
  • driving frequency 650 KHz
  • transducer excitation voltage 116 V
  • T 7 millisecond
  • FIG. 10B an ultrasound image of a clot (right side) and buffer solution (dark left side) within a bovine vessel is shown. The focal point of the therapeutic transducer was advanced along the longitudinal axis of the artery segment from left to right. Ultrasound treatment was stopped at approximately the middle of the clot.
  • FIG. 10B it can be seen that the dark section
  • acoustic emission in the audible range were conducted as a manifestation of the degree of cavitation activity by placing a microphone on a water filled tank.
  • a well defined threshold to the peak intensity was observed.
  • a microphone on the outside of the body of the subject receiving ultrasound treatments can provide an excellent method of obtaining feedback regarding whether cavitation is occurring.
  • an operator is applying ultrasound to a subject, he can watch or listen i a display from the microphone and determine whether cavitation is occurring under parameters where cavitation should be occurring.
  • the microphone output can be fed to a data processor, which can display a warning signal or deactivate the ultrasound device if the device is fully powered, but cavitation is not being detected by the microphone.
  • the feedback can permit an operator to reduce power to the transducer to obtain the minimal amount of power needed to sustain cavitation. This procedure can also be performed while detecting cavitation with an ultrasound imaging transducer.
  • the voltage can be decreased to decrease the ultrasound intensity, but maintain cavitation, i.e., it is an inertial phenomenon.
  • the intensity can be decreased, often by as much as 50% or more to maintain cavitation within the blood vessel but diminish a chance to injure the vessel itself.
  • the cavitation threshold for non-degassed buffer and blood was in the range of 1000 to 1500 W/cm 2 , closest to about 1200 W/cm 2 . With respect to degassed buffer and blood, the cavitation threshold centered around 2000 W/cm 2 .
  • a pulse repetition period T between about 10 and 50 ms created maximum cavitation activity for pulse durations from about 150 ⁇ s to about 700 ⁇ s, correlating to duty ratios ranging from about 15 to 500.
  • a buffer solution was subjected to ultrasound at an intensity 'of 2400 25 W/cm 2 .
  • Example 16 Another experiment similar to that discussed with reference to FIG. 15 was performed, except that the medium tested was blood, rather than a buffer solution. Referring to FIG. 16, the intensity was set at 2400 W/cm 2 and results are shown for pulse durations of 0.100 ms, 0.150 ms, 0.250 ms, 0.400 ms and 0.700 ms for curves 251, 252, 253, 254 and 255 respectively. The parameters for causing cavitation in blood were found to be different than those for causing cavitation in the buffer solution.
  • I 1400 W/cm 2
  • a non-limiting embodiment of an invasive-type ultrasound probe is illustrated generally as probe 1200 in FIG. 22, and in a copending application entitled COOLING SYSTEM FOR ULTRASOUND DEVICE under Application Serial No.
  • Probe 1200 is formed with a tapered member 1225, formed with a proximal end 1229 of diameter A j constructed to be coupled to a source of ultrasound energy such as a transducer 1248.
  • proximal end 1229 is preferably located at a displacement maximum relative to the standing ultrasound wave supported by the overall device. From proximal end 1229, tapered member 1225 tapers to a reduced diameter distal end of diameter A f .
  • Proximal end 1229 must be large enough to receive sufficient energy to treat a thrombus, occlusions and the like. However, in order to provide optimal flexibility, it is desirable to reduce the diameter of distal portions of probe 1200 as much as possible, without significant loss of energy, strength or guidability. Furthermore, the reduction in diameter is preferably accomplished in such a manner as to amplify, or increase the amplitude of, the ultrasound vibrations.
  • Ultrasound device 1200 is understood to operate in the resonant frequency mode; i.e., it supports a standing wave when energized by ultrasonic stimulation at proximal end 1229. Consequently, it is preferred that a cavitation tip 1250 is located at a displacement maximum (anti-node).
  • a probe in accordance with the invention can be bathed with a coolant.
  • the coolant can be directed over and around the probe, for example, by incorporating a sheath 1245 around some or all sections of the probe.
  • Sheathing 1245 may be affixed to the probe at one or more of the displacement nodes of the standing wave. Additional sheathing may be incorporated for providing a passageway for a guidewire or other auxiliary tool which may serve to steer or position the device to its intended location.
  • Sheathing 1245 if formed of a high-strength, thin-walled, low-friction material, preferably polyimide.
  • Probe 1200 includes a horn 1225, having a tapered section T and a first ' -- constant diameter section S, is constructed to be coupled to an ultrasound energy source. Ultrasound energy is provided by the controller at a power source 1246 via a coaxial cable 1247 to a quick disconnect 1249, which connects coaxial cable 1247 to transducer 1248. Transducer 1248 is intimately connected to horn 1225. Probe 1200 also includes a transmission member 1240 coupled to horn 1225 and a tip 1250 coupled to the distal end of transmission member 1240. Ultrasound energy sources disclosed in U.S. Patent No. 5,269,297, and in a copending application entitled FEEDBACK CONTROL SYSTEM FOR ULTRASOUND PROBE under Application Serial No. 60/046,938, filed may 19, 1997, the contents of which are incorporated herein by reference, are suitable.
  • Tip 1250 is coupled to three fine wires joining section 1240 and tip 1250 by means of three openings in tip 1250.
  • the three openings in tip 1250 are spaced so as to form an equilateral triangle, concentric with the central axes of coupling tip 1250.
  • Tip 1250 may also be provided with an opening for a guidewire, and a guidewire tube may be installed in the opening and extended proximally from the distal end.
  • the fine wires may be separately sheathed, and any sheathing may extend between tip 1250 and a coupling joint.
  • Wire 1240 may also be sheathed and the sheathing may be connected to the separate sheathing of the fine wires and may extend proximally to a coolant port through which coolant may be injected to bathe all or part of the transmission member.
  • Example 23
  • Example 25
  • the invasive-type probe was operated under 18 watts of power.
  • a thermocouple in contact with the tip inside the tube provided real time data with respect to temperature. Referring to FIG. 28, the system was initially at 37°C, 10 ml/min of 24°C cooling water was pumped through the tube. As shown in FIG. 28, this reduced temperature at the probe tip to approximately 24°C. At point 681, the probe was turned on and activated with 18 watts of power. This quickly raised the temperature to over 41°C (point 682).
  • the probe temperature increased to only slightly over 27°C, for a temperature increase of only about 3°C.
  • power to the probe was turned off and at point 683, the cooling water was turned off.
  • cooling water * "* was turned back on and at point 685, power to the probe was turned back on.
  • the probe was operated at 18 watts until it was turned off at point 686. As shown, probe temperature only increased about 2°C.
  • Tables 1 and 2 below provide evidence from additional experiments showing a minimal temperature rise when the probe is operated in a pulsed mode, particularly at a duty cycle ratio of 8 or more.
  • invasive-type probes can be operated without cooling fluid and also, without a covering sheath. This will permit the use of substantially smaller guide catheters in view of an overall reduction in the outer dimensions of the probe.
  • Another advantage is a considerable reduction in metal fatigue.
  • the size of the cavitation cloud is related to pulse duration. For example, with the ultrasound generating transducer operating at 40 W/cm 2 average intensity in the focal area, the size of the cavitation cloud increased with increased pulse duration.
  • a small cavitation cloud 3201(a) can be seen with an ultrasound imaging transducer when the ultrasound generating transducer was operated at a pulse duration of 50 ⁇ sec.
  • An operator viewing the procedure could determine that cloud 3201 was smaller than a clot 3302 attached to a vessel wall 3203 and decide to increase the pulse duration.
  • the techniques described for the invasive and non- invasive application of ultrasound are also applicable to systems that promote or focus ultrasound energy to enhance the abso ⁇ tion of drugs, induce apoptosis in cells, and/or treat tissue, tumors, obstructions, and the like, within and without the body, systems to be utilized in or for laproscopic surgery, for ultrasonic scalpels, and to induce tissue hyperthermia such as for cancer radiation therapy, for example.
  • drugs such as streptokinase, urokinase, whose function or efficacy would be enhanced by ultrasound or that would enhance the application of ultrasound at the treatment site, may be infused within the coolant fluid for cooling the ultrasound probe or delivered through a separate passageway within or without the ultrasound probe to the treatment site.
  • Clot lysis Cell function manipulation eg. migration, adhesion, etc.
  • Plaque ablation Drug delivery manipulation Coagulation Drug activity enhancement Cancer treatment
  • Biological product manipulation eg. genes, anti-sense DNA

Abstract

L'invention concerne un appareil et un procédé permettant d'appliquer des ultrasons à un emplacement du corps. Un système de détection de cavitation permet de surveiller l'efficacité, ainsi que la sécurité des ultrasons pendant le traitement aux ultrasons. Un système à ultrasons non invasif (100) comprend un transducteur (110) thérapeutique à ultrasons focalisés.
EP00952781A 1999-03-08 2000-03-08 Procede et appareil de lyse a transducteur double a ultrasons Withdrawn EP1169088A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26434399A 1999-03-08 1999-03-08
US264343 1999-03-08
PCT/US2000/005982 WO2000053263A1 (fr) 1999-03-08 2000-03-08 Procede et appareil de lyse a transducteur double a ultrasons

Publications (1)

Publication Number Publication Date
EP1169088A1 true EP1169088A1 (fr) 2002-01-09

Family

ID=23005628

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00952781A Withdrawn EP1169088A1 (fr) 1999-03-08 2000-03-08 Procede et appareil de lyse a transducteur double a ultrasons

Country Status (5)

Country Link
EP (1) EP1169088A1 (fr)
JP (1) JP2002537955A (fr)
AR (1) AR022879A1 (fr)
CA (1) CA2362689A1 (fr)
WO (1) WO2000053263A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6508774B1 (en) 1999-03-09 2003-01-21 Transurgical, Inc. Hifu applications with feedback control
US20040097996A1 (en) 1999-10-05 2004-05-20 Omnisonics Medical Technologies, Inc. Apparatus and method of removing occlusions using an ultrasonic medical device operating in a transverse mode
US7347855B2 (en) 2001-10-29 2008-03-25 Ultrashape Ltd. Non-invasive ultrasonic body contouring
AU2002217412B2 (en) 2001-01-03 2006-09-14 Ultrashape Ltd. Non-invasive ultrasonic body contouring
DE10158519B4 (de) * 2001-11-29 2005-01-13 Dornier Medtech Holding International Gmbh Stoß- und Druckwellen-Therapiegerät
US7794414B2 (en) 2004-02-09 2010-09-14 Emigrant Bank, N.A. Apparatus and method for an ultrasonic medical device operating in torsional and transverse modes
DE102005037043C5 (de) 2005-08-05 2017-12-14 Dornier Medtech Systems Gmbh Stoßwellentherapiegerät mit Bildgewinnung
US9107798B2 (en) 2006-03-09 2015-08-18 Slender Medical Ltd. Method and system for lipolysis and body contouring
US7828734B2 (en) 2006-03-09 2010-11-09 Slender Medical Ltd. Device for ultrasound monitored tissue treatment
US9028434B2 (en) 2009-05-18 2015-05-12 Olympus Medical Systems Corp. Ultrasound operation apparatus, cavitation control method, and ultrasound transducer control method
US8858439B2 (en) 2009-06-03 2014-10-14 Olympus Medical Systems Corp. Ultrasound operation apparatus, ultrasound operation system, and cavitation suppression method
US8845537B2 (en) 2009-06-03 2014-09-30 Olympus Medical Systems Corp. Ultrasound operation apparatus, ultrasound operation system, and cavitation utilization method
JP5253576B2 (ja) * 2009-07-06 2013-07-31 オリンパスメディカルシステムズ株式会社 超音波手術装置
JP2012035101A (ja) * 2011-10-17 2012-02-23 Nippon Medical School 超音波手術器
WO2017126037A1 (fr) * 2016-01-19 2017-07-27 オリンパス株式会社 Dispositif médical à ultrasons
DE102017219177A1 (de) * 2017-10-26 2019-05-02 Robert Bosch Gmbh System und Verfahren zur Überwachung einer schwingungsübertragenden Einheit, insbesondere einer Sonotrode für eine Ultraschalllyse

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE144124T1 (de) * 1991-12-20 1996-11-15 Technomed Medical Systems Schallwellen aussendende,thermische effekte und kavitationseffekte erzeugende vorrichtung fur die ultraschalltherapie
US5582578A (en) * 1995-08-01 1996-12-10 Duke University Method for the comminution of concretions
US5827204A (en) * 1996-11-26 1998-10-27 Grandia; Willem Medical noninvasive operations using focused modulated high power ultrasound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0053263A1 *

Also Published As

Publication number Publication date
WO2000053263A9 (fr) 2001-10-25
JP2002537955A (ja) 2002-11-12
AR022879A1 (es) 2002-09-04
CA2362689A1 (fr) 2000-09-14
WO2000053263A1 (fr) 2000-09-14

Similar Documents

Publication Publication Date Title
US6113558A (en) Pulsed mode lysis method
US11701134B2 (en) Histotripsy for thrombolysis
US20240058627A1 (en) Ultrasound therapy system
US9700742B2 (en) Methods and systems for non-invasive treatment of tissue using high intensity focused ultrasound therapy
US8298162B2 (en) Skin and adipose tissue treatment by nonfocalized opposing side shock waves
US20060264809A1 (en) Ultrasound catheter with cavitation promoting surface
EP1711109B1 (fr) Production localisee de microbulles et regulation des effets de chauffe et de cavitation au moyen d'ultrason ameliore
US5524620A (en) Ablation of blood thrombi by means of acoustic energy
Bailey et al. Physical mechanisms of the therapeutic effect of ultrasound (a review)
EP1169088A1 (fr) Procede et appareil de lyse a transducteur double a ultrasons
EP2629681B1 (fr) Émetteur-récepteur d'ultrasons
US20100318002A1 (en) Acoustic-Feedback Power Control During Focused Ultrasound Delivery
Xu et al. Dependence of pulsed focused ultrasound induced thrombolysis on duty cycle and cavitation bubble size distribution
WO2009094554A2 (fr) Histotripsie pour thrombolyse
JP2009505769A (ja) 治療トランスデューサ増幅器を有する、画像化及び治療トランスデューサの組合せ
US20110004105A1 (en) Power parameters for ultrasonic catheter
Maxwell et al. Non-invasive thrombolysis induced by histotripsy pulsed cavitation ultrasound therapy
JPWO2004021907A1 (ja) 超音波治療装置
JP2002153482A (ja) 超音波治療装置

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011008

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021001

RBV Designated contracting states (corrected)

Designated state(s): DE FR GB IT